Research

Stay up-to-date on the latest studies and bench-to-bedside therapies at Hopkins.

Thank You

Thank your interest. A staff member from the Clinical Research Office will contact you.

For any additional question, please contact our Clinical Research Office at 410-955-1167.

Nasal potential difference (NPD) measurement performed as part of a clinical trial.

Nasal potential difference (NPD) measurement performed as part of a clinical trial.

Ongoing Trials

Standardized Treatment of Pulmonary Exacerbations II (STOP 2)

PI: Natalie West, MD, MHS

CONTACT: 410-955-1167

PROTOCOL: IRB00090863

The Standardized Treatment of Pulmonary Exacerbations II (STOP 2) is a randomized, controlled, open-label study being done to learn more about CF patients who have a pulmonary exacerbation treated with IV antibiotics. The main purpose of this research is to study the effectiveness and safety of differing durations of IV treatment, given in the hospital or at home for a pulmonary exacerbation in adults with CF.

People 18 years of age and older with CF who are experiencing a pulmonary exacerbation that their doctor wants to clinically treat with IV antibiotics may join. Participation in this study will last approximately 24 to 35 days and will include 3 study visits at Johns Hopkins. Procedures at the Study Visits may include: physical exam, vital signs, height and weight, blood draws, pulmonary function testing, and sputum collection. We are open for enrollment and expect to enroll up to 100 subjects into this study at Johns Hopkins.

You will be compensated for your time. If you expect to be treated with IV antibiotics for a pulmonary exacerbation at home or in
the hospital and are interested, please let us know! We can discuss the study further and answer any questions you may have.

Contact the Research Team
Genetic modifiers of glucose metabolism in CF

PI: Scott Blackman, Md, PhD

CONTACT: 410-955-1167

PROTOCOL: IRB00062031

Contact the Research Team

Contact the Research Team

Close
* Required